https://orcid.org/0000-0001-9022-2229
Current Duke Appointments & Affiliations
Professor of Medicine
·
2024 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2024 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.
Journal article Cancer · April 15, 2026 BACKGROUND: Poly(adenosine diphosphate ribose) polymerase (PARP) is recruited to DNA damage sites along with epigenetic factors such as DNA methyltransferase 1 (DNMT1). Inhibitors of DNMT modulate reactive oxygen species (ROS)-cyclic adenosine monophosphat ... Full text Link to item Cite"Silent Spring" revisited: Implications for breast cancer care.
Journal article Breast · February 2026 Full text Link to item CiteEvolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021.
Journal article NPJ Breast Cancer · November 13, 2025 Tumor biologic risk has replaced anatomic disease burden for guiding chemotherapy use in HR-positive, early-stage breast cancer. Recent surgical trials support less frequent axillary lymph node dissection, potentially impacting incidence of N2-3 diagnoses. ... Full text Link to item CiteRecent Grants
The Duke University - Duke Cancer Institute National Clinical Trials Network Lead Academic Participating Site (UG1) Support Grant
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2032TBCRC Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE_BDT)
Clinical TrialPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2025 - 2031A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
Clinical TrialPrincipal Investigator · Awarded by Indiana University · 2025 - 2030View All Grants
Education
Johns Hopkins University, School of Medicine ·
1995
M.D.